Popular Articles

RegeneRx Working With U.S. Military To Test Tí˛4 Against Exposure To Chemical Agents In The Eye
Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the "Company" or "RegeneRx") announced today that it is collaborating with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University, to evaluate Tí˛4"s (RGN-259 eye drops) ability to prevent or reduce damage to the eye caused by exposure to chemical agents. The ability to prevent or reduce such damage is the focus of substantial efforts by both the military and homeland security. The project will consist of a series of research experiments over the next twelve months with Tí˛4, which is being commercially developed by RegeneRx and is in Phase II clinical trials.

Insight Into Early Schizophrenia May Aid Understanding Of Disease Development, Diagnosis And Treatment
Significant and widespread cognitive problems appear to exist in schizophrenia in its earliest phase, making it very hard for people with the disorder to work, study or be social, according to a new study published by the American Psychological Association.
News of the day
Alkermes Initiates Two New Clinical Trials Of ALKS 33
Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of two new clinical trials of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other nervous system disorders. Study ALK33-004 is a phase 1 clinical trial designed to examine the ability of ALKS 33 to block the effects of an opioid following a single oral dose of ALKS 33 in healthy, non-dependent, opioid-experienced subjects. Study ALK33-003 is a phase 1 clinical trial designed to evaluate the pharmacokinetics, safety and tolerability of multiple doses of ALKS 33 in healthy volunteers.
Nutrition

Cancer Specialists Back New Treatment For UK Patients

Trial reports of the Evolife range of products in France have pointed to significant benefits and enhanced quality of life for cancer patients who use the products before, during and after chemo or radiotherapy treatment. Evolife is a natural range of cosmetics that is 100% dedicated to the support care of cancer patients. The information comes soon after Feel Better Ltd launched the product range in the UK and Ireland which helps relieve painful skin, nails and other debilitating cutaneous side-effects of anti-cancer treatment. Although British trials are in their early stages, the products have been used in France since 2006 by a number of oncologists, nurses, clinics, hospitals and patients. The range has also been launched in 16 other countries around the world. In the UK the brand is already beginning to stock clinics, such as the Harley St Cancer Clinic, and is providing samples for cancer patient makeovers organised by charities such as Look Good Feel Better and Caroline"s Campaign. Verite Reily Collins is a former cancer patient, journalist and editor of online blog after-cancer.com. She said, "Their Evoskin is a fantastic product; the only one I know that you can use on your face and your body. I didn"t believe this at first, but it works! I also gave some Evomucy to a friend who had mouth ulcers from chemo, and he said it was superb!" Evolife provides solutions to problems that previously had few answers. These include cracked and broken nails (Evonail); flaking and broken skin (Evoskin); mouth ulcers (Evomucy), dry mouth (Evodry) and body odour (Evodeo), to name but a few. The range is currently available in the UK and Republic of Ireland through Feel Better Ltd"s website: www.feelbetterduringchemo.com. Trials in France are far more advanced; Dr Radu Vanica, from the Medical Oncology Department of Argenteuil Hospital, Paris, declared: "On several occasions, we have used Evolife products in our service for treating diverse cutaneous-mucous side effects induced by anti-cancer treatments. "Notably, we have used Evonail on patients presenting side effects on their nails after undergoing two different types of anti-tumour treatment. In both cases, the efficiency of the product and the visible improvement were remarkable. "We also used Evoskin, both the Gel Cream and the Spray formats, on patients suffering from acute outbreaks of acne on their faces and bodies as a result of the anti-tumour treatments. After treating with (the) products, we observed a remarkable improvement of the affected area and patients were able to continue with their therapy as scheduled." Patients who use the treatments often see an improved quality of life whilst undergoing treatment. Annick Courtin, Sister of Chemotherapy at the Hospitalisation a Domicile Service in Laon, added: "Each product has its own specific use and their results are exemplary. Many of these products bring comfort to the patients, for example Evomucy enables the patient to rediscover the pleasure of eating and talking without discomfort. Another product, Evonail, enables patients to feel better about themselves with certain patients rediscovering the need to look after their appearances." The effectiveness of the products on chemotherapy patients was discovered when Dr Geraldine Reynaert, a French dermatologist, was transferred to an oncology clinic in Marseille. She noticed that nail problems caused by cancer treatments were similar to those suffered by the psoriasis patients she had treated previously. She decided to try out the Evaux Laboratories product she had been using. Dr Reynaert said: "In light of the outstanding results achieved, I informed the Evaux Laboratoires research and development team who began to work on a specifically adapted Totum Lithium formula* which eventually became EVONAIL. I then tested this product, successfully, on numerous patients." "Since then, I have helped Evolife Laboratoires with their research into various topics corresponding to the different forms of cutaneous and cutaneo-mucous side effects in chemotherapy and radiotherapy." The range of products is unique to Evolife and distributed in the UK by Feel Better Ltd. Dr Emmanuel Achille from The Claude Bernard Oncology Clinic in Metz said: "We are entirely satisfied with the results obtained by using these products that were easily tolerated by the patients. There is no equivalent to these Evolife products on the pharmaceutical-cosmetics market today." Speaking from the ASCO World Oncology Congress in Orlando where Evolife was being launched in the US, Charles Felgate, joint Managing Director of Feel Better Ltd, said: "The reaction from the medical profession has only been matched by the reaction of cancer patients who have been able to go through chemotherapy and radiotherapy with a greater degree of comfort than before. We are proud to bring a product to the UK market which makes a real difference to people"s lives." *[Totum Lithium describes the unique composition of Evaux-les-Bains spring water] http://www.carolinescampaign.org.uk/ http://www.lookgoodfeelbetter.org/ http://after-cancer.com/category/face-and-skin/


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):